IPG Investment Advisors LLC Invests $1.50 Million in IDEXX Laboratories, Inc. $IDXX

Posted by Geri Gentry on May 28th, 2026

IPG Investment Advisors LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,216 shares of the company’s stock, valued at approximately $1,499,000.

Several other institutional investors and hedge funds also recently modified their holdings of IDXX. Empowered Funds LLC boosted its position in shares of IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after buying an additional 95 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter worth about $265,000. Jump Financial LLC boosted its position in shares of IDEXX Laboratories by 1,006.4% in the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after buying an additional 5,032 shares during the period. Cary Street Partners Financial LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter worth about $164,000. Finally, Sei Investments Co. boosted its position in shares of IDEXX Laboratories by 218.7% in the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after buying an additional 82,755 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,758 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the sale, the executive vice president owned 18,141 shares in the company, valued at $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.79% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on IDXX shares. Piper Sandler reduced their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. BTIG Research reduced their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average price target of $751.00.

Get Our Latest Report on IDEXX Laboratories

IDEXX Laboratories Trading Down 1.1%

Shares of IDXX opened at $550.99 on Thursday. The company has a market capitalization of $43.46 billion, a P/E ratio of 40.57, a P/E/G ratio of 3.24 and a beta of 1.58. IDEXX Laboratories, Inc. has a one year low of $504.56 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a 50-day moving average price of $565.23 and a 200 day moving average price of $638.69.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the business posted $2.91 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.